En fase I/II klinisk undersøgelse til evaluering af sikkerheden og effektiviteten af RC288 i behandlingen af solide tumorer
Et multicentret fase I/II klinisk studie til evaluering af sikkerheden og effektiviteten af RC288 til injektion ved behandling af lokalt fremskreden uoperabel eller metastatisk ondartet solid tumor.
The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Heping Liu
- Telefonnummer: +8610-65384976
- E-mail: heping.liu@remegen.com
Studiesteder
-
-
Changsha
-
Hunan, Changsha, Kina
- Ikke rekrutterer endnu
- Hunan Cancer Hospital
-
Kontakt:
- Lin Wu
-
-
Chengdu
-
Sichuan, Chengdu, Kina
- Ikke rekrutterer endnu
- Sichuan Cancer Hospital & Institute
-
Kontakt:
- Huangming Hong
-
-
Fuzhou
-
Fujian, Fuzhou, Kina
- Ikke rekrutterer endnu
- Fujian Cancer Hospital
-
Kontakt:
- Zhangzhou Huang
-
Fujian, Fuzhou, Kina
- Ikke rekrutterer endnu
- Fujian Medical University Union Hospital
-
Kontakt:
- Jinhuo Lai
-
-
Guangzhou
-
Guangdong, Guangzhou, Kina
- Ikke rekrutterer endnu
- Sun Yat sen University Cancer Center
-
Kontakt:
- Yanxia Shi
-
Kontakt:
- Yonghong Li
-
-
Guiyang
-
Guizhou, Guiyang, Kina
- Ikke rekrutterer endnu
- The Affiliated Hospital of Guizhou Medical University
-
Kontakt:
- Huixin Ge
-
-
Haerbin
-
Heilongjiang, Haerbin, Kina
- Ikke rekrutterer endnu
- Harbin Medical University Cancer Hospital
-
Kontakt:
- Baogang Liu
-
-
Hunan
-
Changsha, Hunan, Kina
- Rekruttering
- Hunan Cancer Hospital
-
Kontakt:
- Weiqing Han
- Telefonnummer: +86731-89762271
- E-mail: md70210@sina.com
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina
- Rekruttering
- Nanjing Drum Tower Hospital
-
-
Jinan
-
Shandong, Jinan, Kina
- Ikke rekrutterer endnu
- Cancer Hospital of Shandong First Medical University Cancer Hospital
-
Kontakt:
- Juan Li
-
Kontakt:
- Benkui Zou
-
Shandong, Jinan, Kina
- Rekruttering
- Shanxi Cancer Hospital
-
-
Shanxi
-
Shanxi, Shanxi, Kina
- Rekruttering
- Shanxi Cancer Hospital
-
-
Taizhou
-
Zhejiang, Taizhou, Kina
- Ikke rekrutterer endnu
- Taizhou Hospital of Zhejiang Province
-
-
Wenzhou
-
Zhejiang, Wenzhou, Kina
- Ikke rekrutterer endnu
- The First Affiliated Hospital of Wenzhou Medical University
-
Kontakt:
- Wei Chen
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Voluntarily participate in this study, sign the informed consent form, and be able to adhere to the study protocol;
- Age between 18 and 75 years (including 18 and 75 years);
- ECOG PS score of 0 or 1;
- Expected survival ≥12 weeks;
- According to RECIST v1.1 criteria, based on imaging examinations, there is at least one measurable target lesion;
- Sufficient bone marrow, liver, kidney, and blood clotting function
Exclusion Criteria:
- Pregnant, breastfeeding, or intending to become pregnant subjects.
- Subjects with brain metastases.
- Subjects with unresolved toxicities from prior anti-tumor therapy not recovered to NCI-CTCAE v6.0 Grade 1.
- Subjects with known hypersensitivity or delayed allergic reactions to any component of the investigational drug or similar drugs.
- Subjects with acute, chronic, or symptomatic infections.
- Subjects with uncontrolled cardiovascular diseases.
- Subjects with confirmed or suspected interstitial lung disease (ILD), drug-related pneumonia, radiation pneumonitis, severely impaired pulmonary function, or other pulmonary diseases.
- History of underlying pulmonary disease.
- Subjects with a history of cirrhosis (Child-Pugh B or C class).
- Clinically significant gastrointestinal disease.
- Subjects with uncontrolled diabetes (HbA1c ≥ 10%).
- Occurrence of hemorrhagic events of Grade ≥2 per NCI CTCAE (v6.0) within 4 weeks prior to screening; or clinical manifestations suggestive of a significant bleeding tendency within 4 weeks prior to screening.
- Imaging during the screening period shows tumor invasion or involvement of vital organs, with imaging evidence judged by the investigator to indicate a risk of bleeding or fistula formation.
- History of arterial/venous thromboembolic events within 6 months prior to the first dose.
- Presence of pericardial effusion or cardiac tamponade, or third-space fluid accumulation that, in the investigator's judgment, cannot be stably controlled by drainage or other methods.
- History of active autoimmune disease requiring systemic therapy within the past 2 years.
- History of other invasive malignancies within 5 years prior to the first dose, or evidence of residual disease from any previously diagnosed malignancy.
- History of other acquired or congenital immunodeficiency diseases, or history of organ transplantation.
- History of or current poorly controlled psychiatric disorder.
- Poor compliance, and patients who are expected to be unable to cooperate with the completion of trial procedures.
- Presence of any other disease, metabolic abnormality, physical examination finding, or laboratory abnormality that, in the investigator's judgment, gives reasonable suspicion of a condition that contraindicates the use of the investigational drug, may affect the interpretation of study results, or places the patient at high risk.
- Local or systemic diseases not caused by malignancy, or diseases or symptoms secondary to the tumor, which may lead to higher medical risks and/or uncertainty in survival assessment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: RC288 (Phase I, dose escalation)
There are six predefined escalating dose levels. |
Intravenous (IV) administration of RC288. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study. |
|
Eksperimentel: RC288 (Phase II, dose expansion)
In the multi-indication cohort expansion phase, further assess the efficacy and safety of RC288 in various cancer types using the RP2D. |
Intravenous (IV) administration of RC288. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Dosisbegrænsende toksicitet (DLT)
Tidsramme: 24 måneder
|
24 måneder
|
|
Forekomst og sværhedsgrad af bivirkninger/alvorlige bivirkninger (gradet i henhold til NCI CTCAE v6.0)
Tidsramme: 24 måneder
|
24 måneder
|
|
Bestem RP2D af RC288
Tidsramme: 24 måneder
|
24 måneder
|
|
MTD og/eller MAD
Tidsramme: 24 måneder
|
24 måneder
|
|
Prostatakræft-kohorte: Undersøger-vurderet ORR i henhold til RECIST v1.1-kriterier og PCWG3-kriterier
Tidsramme: 24 måneder
|
24 måneder
|
|
Ikke-prostatakræft-kohorte: Undersøgerens vurdering af ORR i henhold til RECIST v1.1-kriterierne
Tidsramme: 24 måneder
|
24 måneder
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- RC288-C101
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .